

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Farzan Rastinejad et al.

APPLICATION NO.: 09/443,542

: Examiner: Dr. Jerome Goldberger

FILING DATE: November 19, 1999

: Group Art Unit: 1614

TITLE: METHODS AND COMPOSITIONS FOR
RESTORING CONFORMATIONAL
STABILITY OF A PROTEIN OF THE P53
FAMILY

Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ. AND REMARKS

It is requested that the reference listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). Since this Information Disclosure Statement is being filed after mailing of a **non-final Official Action**, Applicants hereby petition for consideration of the reference under 37 CFR 1.97(c)(2). The Patent Office is authorized to charge the Petition Fee, 37 CFR 1.17(p), of \$240.00, or any other needed fee or fee amount, to Deposit Account 16-1445. A duplicate of this paper is enclosed.

Remarks

The attached reference published in 2002, Bykov et al., follows on the footsteps of the present Applicants' pioneering work on stabilizing working conformations of p53 with small molecules. Following screening of a library, Bykov et al. disclose the compound "PRIMA-1" which restores the active conformation of mutant p53 *in vitro* and in living cells, and *in vivo* studies revealed an anti-tumor effect.

Applicants again respectfully request that the Patent Office accord to them broad claims that reflect the pioneering and important science disclosed in the present application. A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 3/11/02

E. Victor Donahue
Attorney for Applicant(s)
Reg. No. 35,492

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5612
(212) 733-2739

RECEIVED
MAR 13 2002
TECH CENTER 1600/2900
02 MAR 12 PM 1:05
RECEIVED
MAR 13 2002
TECH CENTER 1600/2900